| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Melanoma antigen recognized by T-cells 1, MART-1, Antigen LB39-AA, Antigen SK29-AA, Protein Melan-A, MLANA, MART1 |
| Entrez GeneID | 2315 |
| WB Predicted band size | 13.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This MART-1/Melan-A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 34-60 amino acids from the Central region of human MART-1/Melan-A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于MART-1/Melan-A抗体的代表性文献摘要概括：
---
1. **文献名称**：*Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection*
**作者**：Kawakami, Y. et al. (1994)
**摘要**：首次克隆并鉴定了MART-1(Melanoma Antigen Recognized by T cells-1)基因，证明其在黑色素瘤细胞中特异性表达，并开发了针对该抗原的单克隆抗体，为后续免疫治疗研究奠定基础。
---
2. **文献名称**：*A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas*
**作者**：Coulie, P.G. et al. (1994)
**摘要**：独立发现Melan-A(后证实与MART-1为同一抗原)，阐明其作为HLA-A2限制性T细胞识别靶点的功能，并验证其抗体在黑色素瘤组织中的特异性染色能力。
---
3. **文献名称**：*Monoclonal antibody A103: Immunoreactivity with human melanocytic lesions*
**作者**：Jungbluth, A.A. et al. (1998)
**摘要**：评估单克隆抗体A103(抗MART-1/Melan-A)在多种黑色素瘤及正常黑色素细胞中的免疫组化表现，证实其高特异性，并建议作为黑色素瘤病理诊断的关键标志物。
---
4. **文献名称**：*MART-1: A novel melanocyte-specific marker in the diagnosis of melanoma*
**作者**：Busam, K.J. et al. (1998)
**摘要**：系统分析MART-1抗体在鉴别良性痣与恶性黑色素瘤中的应用，强调其在诊断转移性黑色素瘤中的敏感性和特异性，优于传统标志物如S100和HMB-45.
---
这些研究涵盖了MART-1/Melan-A抗体的发现、验证及临床应用，适用于黑色素瘤诊断、免疫治疗机制探索及病理学研究。
MART-1/Melan-A, a protein encoded by the *MLANA* gene, is a lineage-specific antigen predominantly expressed in melanocytes and melanoma cells. Discovered in 1994. it was initially identified as a target of tumor-infiltrating CD8+ T lymphocytes in melanoma patients, highlighting its role in immune recognition. Structurally, it is a transmembrane protein localized to melanosomes, organelles involved in melanin synthesis. Though its exact biochemical function remains unclear, MART-1/Melan-A is linked to melanosome maturation and pigment production.
Antibodies against MART-1/Melan-A are widely used in diagnostic pathology to confirm melanocytic origin in tumors. They exhibit high sensitivity for melanoma, aiding in distinguishing it from other malignancies (e.g., carcinoma or sarcoma). However, staining specificity is context-dependent, as non-melanocytic tumors (e.g., adrenal cortical carcinoma) may rarely express it. In research, these antibodies help study melanocyte biology, tumor immunology, and therapeutic targets, such as adoptive T-cell therapies targeting MART-1/Melan-A peptides.
Clinically, MART-1/Melan-A immunohistochemistry complements other markers (e.g., SOX10. HMB-45) in evaluating ambiguous lesions. Limitations include variable expression in desmoplastic or spindle-cell melanomas. Despite this, it remains a cornerstone in melanoma diagnostics and a symbol of early advances in cancer immunology.
×
